The proprietary formulation of ketamine and optimized route of administration in scope for this agreement has the potential to supply the very best affected individual knowledge and results In combination with deepening Awakn's IP moat. Awakn is organizing for the new formulation being evaluated in its Section III scientific trial. http://psychedelicsmokebbq.com